Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States (Unknown)
- New search for: Xue, Xiangzhong
- New search for: Truong, Bang
- New search for: Qian, Jingjing
- New search for: Xue, Xiangzhong
- New search for: Truong, Bang
- New search for: Qian, Jingjing
In:
Expert Opinion on Biological Therapy
;
23
, 8
;
841-849
;
2023
- Article (Journal) / Electronic Resource
-
Title:Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States
-
Contributors:
-
Published in:Expert Opinion on Biological Therapy ; 23, 8 ; 841-849
-
Publisher:
- New search for: Taylor & Francis
-
Publication date:2023-08-03
-
Size:9 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:Unknown
-
Keywords:
-
Source:
Table of contents – Volume 23, Issue 8
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 651
-
Preparing for the third decade of biosimilarsAbraham, Ivo et al. | 2023
- 653
-
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countriesCalamia, Matthias / Abraham, Ivo et al. | 2023
- 659
-
Biosimilars for the next decade in Latin America: a window of opportunityBas, Tomas Gabriel et al. | 2023
- 671
-
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African regionAlkhatib, Nimer S / Halloush, Shiraz / Abraham, Ivo et al. | 2023
- 679
-
The landscape of biosimilars in Saudi Arabia: preparing for the next decadeAlmutairi, Abdulaali R. / Al-Samil, Ali M. / Alsayyari, Abdulaziz / Yousef, Consuela Cheriece / Khan, Mansoor Ahmed / Alhamdan, Hani S. / Al-Jedai, Ahmed et al. | 2023
- 689
-
Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South AsiaSharma, Ashish / Kumar, Nilesh / Parachuri, Nikulaa / Loewenstein, Anat / Bandello, Francesco / Kuppermann, Baruch D et al. | 2023
- 693
-
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspectiveJoshi, Shashank R / Mittra, Shivani / Raj, Praveen / Suvarna, Viraj Ramesh / Athalye, Sandeep N et al. | 2023
- 705
-
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trialGuo, Yinhan / Guo, Tingting / Di, Yujing / Xu, Wenyu / Hu, Zhitian / Xiao, Yanfeng / Yu, Heze / Hou, Jie et al. | 2023
- 717
-
Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group studyZhou, Wenjia / Wang, Meng / Yu, Yunli / Wang, Ji / Wu, Yanni / Yang, Guiyu / Yu, Haoyu / Li, Jing / Zhou, Liang / Zhang, Quanying et al. | 2023
- 727
-
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjectsZhang, Qin / Sun, Cheng / Wu, Jinying / Wu, Juan / Zhang, Xuan / Liu, Yueyue / Dou, Changlin / Qin, Huilin / Zhang, Qian / Zhou, Renpeng et al. | 2023
- 737
-
A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of KoreaJo, Jae-Cheol / Jeon, Youngwoo / Kim, DaJung / Yang, Deok-Hwan / Lee, Won Sik / Choi, Yoon Seok / Yi, Jun Ho / Yoon, Dok Hyun / Kong, Jee Hyun / Choe, Jung-Yoon et al. | 2023
- 749
-
GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilarvon Richter, Oliver / O’Reilly, Terry / Guerrieri, Davide / Fan, Jamie / Fey, Constanze / Schussler, Steven / Furlan, Fabricio / Lemke, Lena et al. | 2023
- 759
-
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasisFeldman, Steven R / Reznichenko, Nataliya / Berti, Fausto / Duijzings, Paul / Ruffieux, Ruth / Otto, Hendrik / Haliduola, Halimu N / Leutz, Steffen / Stroissnig, Heimo et al. | 2023
- 773
-
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adultsWynne, Christopher / Schwabe, Christian / Stroissnig, Heimo / Dias, Roshan / Sobierska, Joanna / Guenzi, Eric / Otto, Hendrik / Sattar, Abid / Haliduola, Halimu N / Edwald, Elin et al. | 2023
- 781
-
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringeDamjanov, Nemanja / Kirvalidze, Nana / Kurashvili, Nana / Berti, Fausto / Steiger, Matjaz / Sobierska, Joanna / Guenzi, Eric / Otto, Hendrik / Sattar, Abid / Haliduola, Halimu N. et al. | 2023
- 791
-
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)Bokemeyer, Bernd / Hlavaty, Tibor / Allez, Matthieu / Selema, Pamela / Moosavi, Shahrzad / Cadatal, Mary Jane / Fowler, Heather / Mueller, Markus / Liau, Katherine F / Gisbert, Javier P et al. | 2023
- 801
-
Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidanceMeijboom, Rosanne W / Barbier, Liese / Druedahl, Louise C / Sarnola, Kati / Tolonen, Hanna M / Gardarsdottir, Helga / Egberts, Toine C G / Giezen, Thijs J et al. | 2023
- 819
-
Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in AustraliaAnderson, Emilia / Waller, Karen / Tamilarasan, Aravind Gokul / Lin, Huiyu / Paramsothy, Sudarshan / Leong, Rupert W et al. | 2023
- 827
-
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter surveySarlós, Patrícia / Bikar, Alexander / Farkas, Nelli / Resál, Tamás / Szepes, Zoltán / Farkas, Klaudia / Nagy, Ferenc / Vincze, Áron / Miheller, Pal / Molnár, Tamás et al. | 2023
- 833
-
Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseasesUlu, Kadir / Çakan, Mustafa / Çağlayan, Şengül / Yiğit, Ramazan Emre / Demir, Ferhat / Coşkuner, Taner / Kardeş, Esra / Sözeri, Betül et al. | 2023
- 841
-
Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United StatesXue, Xiangzhong / Truong, Bang / Qian, Jingjing et al. | 2023
- 851
-
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)Sharma, Ashish / Holz, Frank G / Regillo, Carl D / Freund, K Bailey / Sarraf, David / Khanani, Arshad M. / Baumal, Caroline / Holekamp, Nancy / Tadayoni, Ramin / Kumar, Nilesh et al. | 2023